Abstract
Gout disease is an inflammatory arthritis that arises due to the accumulation of monosodium urate crystals (MSU) around the joints and in tissues. Clinical manifestation of metabolic diseases leading to secondary hyperuricemia most predominantly occurs in the form of gouty arthritis. Hyperuricemia and gout may develop during the course of glycogen storage diseases (GSD), particularly in GSD type I, which involves the liver. On the other hand, during the course of GSD type V (GSDV, McArdle’s disease), which merely affects the muscle tissue due to the deficiency of the enzyme myophosphorylase, hyperuricemia and/or gout is rarely an expected symptom. These patients may mistakenly be diagnosed as having idiopathic hyperuricemia and associated gout, leading to the underlying secondary causes be overlooked and thus, diagnostic delays may occur. In this case report, we present a premenopausal female patient who experienced flare-ups of chronic arthritis while on disease-modifying antirheumatic drugs and intraarticular steroids due to a diagnosis of undifferentiated arthritis. The patient was initially suspected of having gouty arthritis because elevated concentrations of uric acid were incidentally detected, but then, a diagnosis of asymptomatic GSDV was made owing to elevated concentrations of muscle enzymes during colchicine use. Our aims were to remind rheumatologists of the phenomenon of “myogenic hyperuricemia” and to discuss the potential causes of hyperuricemia that develop during GSD along with the available literature.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Robinson PC (2018) Gout - an update of aetiology, genetics, co-morbidities and management. Maturitas. 118:67–73
Puig JG, de Miguel E, Mateos FA, Miranda E, Romera NM, Espinosa A, Gijón J (1992) McArdle's disease and gout. Muscle Nerve 15:822–828
Hardiman O, Farrell M, McElvaney G, Tipton K, Staunton H (1987) Hyperuricemia in type V glycogenosis. Neurology. 37:728–729
Green HL, Wilson FA, Hefferan P, Terrs' AB, Moran JR, Slonim AE, Claus TH, Burr IM (1978) ATP depletion, a possible role in the pathogenesis of hyperuricemia in glycogen storage disease type I. J Clin Invest 62:321–328
Jinnai K, Kono N, Yamamoto Y, Kanda F, Ohno S, Tsutsumi M, Yamada Y, Kawachi M, Tarui S, Fujita T (1993) Glycogenosis type V (McArdle's disease) with hyperuricemia. A case report and clinical investigation. Eur Neurol 33:204–207
Mineo I, Kono N, Hara N, Shimizu T, Yamada Y, Kawachi M, Kiyokawa H, Wang YL, Tarui S (1987) Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med 317:75–80
Scalco RS, Chatfield S, Godfrey R, Pattni J, Ellerton C, Beggs A, Brady S, Wakelin A, Holton JL, Quinlivan R (2014) From exercise intolerance to functional improvement: the second wind phenomenon in the identification of McArdle disease. Arq Neuropsiquiatr 72:538–541
Hara N, Mineo I, Kono N, Kiyokawa H, Kawachi M, Yamada Y et al (1989) Myogenic hyperuricemia: a comparative study between type V and type VII glycogenosis. Adv Exp Med Biol 253A:381–386
Pearson CM, Rimer DG, Mommaerts WF (1961) A metabolic myopathy due to absence of muscle phosphorylase. Am J Med 30:502–517
Choı HK (2008) Clinical features. Epidemiology, pathology and pathogenesis. In: Klippel JH (ed) primer on the rheumatic diseases, 13th edn. Springer, New York, pp 241–257
Hicks J, Wartchow E, Mierau G (2011) Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastruct Pathol 35:183–196
Zhang B, Zeng X (2016) Tophaceous gout in a female premenopausal patient with an unexpected diagnosis of glycogen storage disease type Ia: a case report and literature review. Clin Rheumatol 35:2851–2856
Kono N, Mineo I, Tarui S (1987) Reply from the authors: hyperuricemia in type V glycogenosis. Neurology. 37:729
Tarnopolsky MA (2016) Metabolic myopathies. Continuum (Minneap Minn). 22(6, muscle and neuromuscular junction disorders):1829–1851
Horneff G, Paetzke I, Neuen-Jacob E (2001) Glycogenosis type V (McArdle's disease) mimicking atypical myositis. Clin Rheumatol 20:57–60
Author information
Authors and Affiliations
Contributions
Döndü ÜSKÜDAR CANSU: Contributed to project design, writing, editing, and critical revision of the manuscript and has read and approved the manuscript.
Bahattin ERDOĞAN: Contributed by drafting the manuscript, has read and approved the manuscript.
Cengiz KORKMAZ: Contributed to project design, editing, and critical revision of the manuscript and has read and approved the manuscript.
Corresponding author
Ethics declarations
Disclosures
None.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from our patient included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Üsküdar Cansu, D., Erdoğan, B. & Korkmaz, C. Can hyperuricemia predict glycogen storage disease (McArdle’s disease) in rheumatology practice? (Myogenic hyperuricemia). Clin Rheumatol 38, 2941–2948 (2019). https://doi.org/10.1007/s10067-019-04572-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-019-04572-8